The progress achieved in anticancer therapy in recent years has been paralleled by an increase in the survival of women with cancer globally. Nonetheless, the gonadotoxic impact of anticancer drugs has led to ovarian failure in treated women. While there are documented cases of successful ovarian tissue transplants resulting in restored fertility and childbirth, challenges persist, including suboptimal functional recovery and limited graft lifespan. Melatonin, an inert hormone primarily secreted by the mammalian pineal gland, exhibits diverse physiological functions, including antioxidative, anti-inflammatory, anti-apoptotic, and angiogenesis-regulating properties. Consequently, researchers have explored melatonin as a modulator to enhance graft function recovery in ovarian transplantation experiments, yielding promising outcomes. This review examines the relevant literature, consolidating findings that underscore the positive effects of melatonin in safeguarding the morphology and structure of transplanted ovarian tissues, facilitating graft function recovery, and extending lifespan. The amassed evidence supports the consideration of melatonin as a prospective protective agent for human ovarian tissue transplantation in the future.

近年来，抗癌治疗取得的进展与全球癌症女性生存率的提高同步。尽管如此，抗癌药物的性腺毒性影响已导致接受治疗的女性卵巢衰竭。尽管有记录表明卵巢组织移植成功恢复了生育能力和分娩能力，但挑战仍然存在，包括功能恢复不佳和移植物寿命有限。褪黑激素是一种主要由哺乳动物松果体分泌的惰性激素，具有多种生理功能，包括抗氧化、抗炎、抗凋亡和血管生成调节特性。因此，研究人员在卵巢移植实验中探索了褪黑激素作为调节剂来增强移植物功能恢复，并取得了有希望的结果。本综述查阅了相关文献，巩固了强调褪黑激素在保护移植卵巢组织的形态和结构、促进移植物功能恢复和延长寿命方面的积极作用的研究结果。积累的证据支持考虑将褪黑激素作为未来人类卵巢组织移植的前瞻性保护剂。